Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.30 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.30 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.30 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21503810 | 1.00 | C3AR1 (0.33) | C3AR1SIRT5SIRT2EPHX1REN | |
| SCHEMBL21914903 | 0.91 | C3AR1 (0.34) | C3AR1SIRT5SIRT6SIRT1CTDSP1 | |
| SCHEMBL21914949 | 0.91 | C3AR1 (0.34) | C3AR1SIRT5SIRT6SIRT1CTDSP1 | |
| SCHEMBL17992599 | 0.91 | C3AR1 (0.34) | C3AR1SIRT5SIRT6SIRT1CTDSP1 | |
| SCHEMBL24173258 | 0.91 | C3AR1 (0.34) | C3AR1SIRT5SIRT6SIRT1CTDSP1 | |
| SCHEMBL22198634 | 0.91 | C3AR1 (0.34) | C3AR1SIRT5SIRT6SIRT1CTDSP1 | |
| SCHEMBL20803561 | 0.91 | C3AR1 (0.34) | C3AR1SIRT5SIRT6SIRT1CTDSP1 | |
| SCHEMBL22692383 | 0.91 | C3AR1 (0.34) | C3AR1SIRT5SIRT6SIRT1CTDSP1 | |
| SCHEMBL23106118 | 0.90 | NPY4R (0.38) | SIRT5SIRT2 | |
| SCHEMBL21503838 | 0.90 | SIRT5 (0.35) | C3AR1SIRT5SIRT2EPHX1SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210079039-A1 | COMPOSITIONS AND METHODS FOR THE SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | AVELAS ACQUISITION CORPORATION | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210079039-A1 | COMPOSITIONS AND METHODS FOR THE SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | PAICS, ANXA3, APOB | C3AR1 452/4885SIRT5 3145/4885SIRT2 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.